Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Biogen gives up seeking European approval for aducanumab

By Brian Buntz | April 22, 2022

AduhelmAfter winning FDA approval for the controversial Alzheimer’s drug Aduhelm (aducanumab) in June 2021, Biogen (Nasdaq:BIIB) has encountered a string of setbacks.

Most recently, the company has decided to yank its applications for market approval after the European Medicines Agency (EMA) recommended the refusal of the marketing authorization for Aduhelm in December 2021.

At that time, Biogen announced that it would fight the decision.

In April, the company notified EMA that its decision to withdraw its application was “based on interactions with the CHMP [Committee for Medicinal Products for Human Use] indicating that the data provided thus far would not be sufficient to support a positive opinion on the marketing authorization of Aduhelm (aducanumab).”

Aduhelm“We are thankful to the patients, caregivers and physicians that supported the re-examination process as part of the EMA review,” said Dr. Priya Singhal, head of global safety and regulatory sciences and interim head of R&D at Biogen, in a press release. “We stand by the safety and efficacy of aducanumab, and we look forward to upcoming data readouts to continue to provide important information on the science of this new class of compound.”

Sales of the drug in the U.S. have sputtered since launch and the CMS’s decision to limit coverage of it to clinical trial participants have been a further headwind.

BIIB shares dropped 3.85% to $209.99. In June 2021, the company’s share price almost reached $400.

Biogen has announced a series of measures to defray costs, including restructuring and a decision to sell its equity stake in Samsung Bioepis joint venture for up to $2.3 billion.


Filed Under: Biologics, Drug Discovery and Development, Neurological Disease
Tagged With: Aducanumab, Aduhelm, Biogen, CMS, EMA, European Medicines Agency, FDA
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

PolarityTE
How PolarityTE aims to help heal chronic wounds
Axogen
Axogen announces positive topline data from Phase 3 nerve graft study
Janssen
Janssen’s company group chairman dishes on growth strategy
AstraZeneca
Imfinzi with chemotherapy gets FDA priority review for locally advanced or metastatic biliary tract cancer

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50